Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2013

View Archived Issues

Nanoparticle-mediated vaccine delivery system for pulmonary immunization

DCBCI-0901 shows promising activity in in vitro and in vivo cancer models

KKHP-60159 reported to have ideal antipsychotic profile

Dual D2 and H3 blockade as a putative strategy for schizophrenia: Angita's AG-0098

ChemoCentryx describes novel small-molecule inhibitors of CCR1 and CCR6

Patisiran receives FDA fast track designation for TTR-mediated amyloidosis

Affinium obtains QIDP designation for AFN-1252, completes dosing in study of new prodrug

Nationwide Children's Hospital discloses new antimicrobial peptides for bacterial infections

Novel HBV expression inhibitors patented by Isis Pharmaceuticals

GlaxoSmithKline prepares new RORgamma modulators

Janssen Pharmaceutica synthesizes new antibacterial agents

ME-3398, a novel PDE10A inhibitor for the treatment of schizophrenia

Herceptin conjugate could penetrate blood-tumor barrier better than Herceptin

Ligand begins phase I trial of LGD-6972 for type 2 diabetes

Servier's voluntary public offer for outstanding shares in Egis Pharmaceuticals closes

Innate Pharma presents a novel cytotoxic antibody against KIR3DL2-expressing cancers

FDA considers NDA filing for eteplirsen premature

BioFocus signs agreement with Biogen Idec in target discovery for scleroderma

FDA grants QIDP designation to oritavancin

Preclinical antiviral efficacy seen in Tekmira's TKM-Ebola and TKM-Marburg programs

Japanese NHI price listing of Kadcyla postponed

Anacor reports findings for AN-2728 in pediatric and adolescent patients with atopic dermatitis

Boehringer Ingelheim seeks European approval of tiotropium Respimat for asthma

Isis earns milestone payment for phase II study of ISIS-SMNRx

Pieris achieves new milestone in Daiichi Sankyo Anticalin collaboration

Immunocore achieves first milestone under collaboration with GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...